NASDAQ:GRTSGritstone Oncology Stock Price, Forecast & News

Gritstone Oncology's stock was trading at $6.67 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, GRTS shares have increased by 0.9% and is now trading at $6.73. View which stocks have been most impacted by Coronavirus.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Gritstone Oncology in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Gritstone Oncology.

Gritstone Oncology is scheduled to release its next quarterly earnings announcement on Monday, August 10th 2020. View our earnings forecast for Gritstone Oncology.

Gritstone Oncology Inc (NASDAQ:GRTS) issued its quarterly earnings data on Thursday, May, 7th. The company reported ($0.71) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.73) by $0.02. The firm earned $1.26 million during the quarter, compared to analyst estimates of $1.20 million. Gritstone Oncology had a negative net margin of 2,397.90% and a negative return on equity of 69.76%. View Gritstone Oncology's earnings history.

3 Wall Street analysts have issued 1 year price objectives for Gritstone Oncology's stock. Their forecasts range from $17.00 to $17.00. On average, they anticipate Gritstone Oncology's stock price to reach $17.00 in the next twelve months. This suggests a possible upside of 152.6% from the stock's current price. View analysts' price targets for Gritstone Oncology.

News coverage about GRTS stock has trended extremely negative on Saturday, InfoTrie Sentiment reports. InfoTrie scores the sentiment of press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Gritstone Oncology earned a coverage optimism score of -4.4 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 5.0 out of 10, indicating that recent press coverage is somewhat likely to have an effect on the stock's share price in the near future. View the latest news aboutGritstone Oncology.

Some companies that are related to Gritstone Oncology include Orchard Therapeutics (ORTX), Replimune Group (REPL), Krystal Biotech (KRYS), Sorrento Therapeutics (SRNE), Avrobio (AVRO), BioCryst Pharmaceuticals (BCRX), AVITA MED LTD/S (RCEL), Cellectis (CLLS), Aerie Pharmaceuticals (AERI), Vericel (VCEL), Osiris Therapeutics (OSIR), Oyster Point Pharma (OYST), AVITA MED LTD/S (AVMXY), Agenus (AGEN) and Aptose Biosciences (APTO). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Gritstone Oncology investors own include Clovis Oncology (CLVS), Crispr Therapeutics (CRSP), VBI Vaccines (VBIV), Agile Therapeutics (AGRX), Amarin (AMRN), Sorrento Therapeutics (SRNE), Sarepta Therapeutics (SRPT), AbbVie (ABBV), Advanced Micro Devices (AMD) and Axsome Therapeutics (AXSM).

(GRTS) raised $85 million in an IPO on Friday, September 28th 2018. The company issued 6,100,000 shares at $13.00-$15.00 per share. Goldman Sachs, Cowen and Barclays acted as the underwriters for the IPO and BTIG was co-manager.

Gritstone Oncology trades on the NASDAQ under the ticker symbol "GRTS."

Gritstone Oncology's stock is owned by many different retail and institutional investors. Top institutional shareholders include Redmile Group LLC (8.23%), Casdin Capital LLC (6.09%), BlackRock Inc. (5.88%), Victory Capital Management Inc. (0.95%), Victory Capital Management Inc. (0.94%) and Ensign Peak Advisors Inc (0.94%). Company insiders that own Gritstone Oncology stock include Nicholas Simon and Raphael Rousseau. View institutional ownership trends for Gritstone Oncology.

GRTS stock was sold by a variety of institutional investors in the last quarter, including Redmile Group LLC, Ensign Peak Advisors Inc, UBS Group AG, Victory Capital Management Inc., Victory Capital Management Inc., and First Trust Advisors LP. View insider buying and selling activity for Gritstone Oncology.

GRTS stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Casdin Capital LLC, Russell Investments Group Ltd., Squarepoint Ops LLC, Geode Capital Management LLC, JPMorgan Chase & Co., Nuveen Asset Management LLC, and Alliancebernstein L.P.. View insider buying and selling activity for Gritstone Oncology.

Shares of GRTS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of GRTS stock can currently be purchased for approximately $6.73.

Gritstone Oncology has a market capitalization of $250.76 million and generates $4.36 million in revenue each year. The company earns $-94,430,000.00 in net income (profit) each year or ($2.81) on an earnings per share basis. Gritstone Oncology employs 113 workers across the globe.

The official website for Gritstone Oncology is www.gritstoneoncology.com.

Gritstone Oncology's mailing address is 5858 HORTON STREET SUITE 210, EMERYVILLE CA, 94608. The company can be reached via phone at 510-871-6100 or via email at www.gritstoneoncology.com.